Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
REMBRANDT Trial
NCT06305559Phase 3Active, not recruiting
- Sponsor
- NewAmsterdam Pharma
- Start
- May 2024
- Primary completion
- Nov 2027
- Modality
- Classical Binding Small Molecules, Nucleic Acid-Directed Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of obicetrapib in atherosclerotic cardiovascular disease (ASCVD), sponsored by NewAmsterdam Pharma. Started May 2024; status: active, not recruiting.
02
Drugs
obicetrapib
03
Conditions
atherosclerotic cardiovascular disease (ASCVD)
Beyond the preview
Go deeper on NCT06305559.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06305559.